Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of NKTR revenue | Skew |
|---|---|---|---|
| KRCKilroy Realty Corp | 1.60% | 35.91% | 0.0× |
| AZNAstraZeneca | 0.01% | 17.00% | 1,394× |
| PFEPfizer Inc. | 0.01% | 12.00% | 1,133× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
$22M relationship
basisNKTR fy2025 · closed 2025-12 $55M
FILING10-K0001193125-26-104547cik 0000906709
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
$10M relationship
basisNKTR fy2025 · closed 2025-12 $55M
FILING
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
$9M relationship1,394× more of NKTR’s book than AZN’s
basisNKTR fy2025 · closed 2025-12 $55MAZN fy2025 · closed 2025-12 $77.0B
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
$7M relationship1,133× more of NKTR’s book than PFE’s
basisNKTR fy2025 · closed 2025-12 $55MPFE fy2025 · closed 2025-12 $62.6B
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
$6M relationship
basisNKTR fy2025 · closed 2025-12 $55M
FILING10-K0001193125-26-104547
“On December 2, 2024, we completed the sale of the Facility and assigned our manufacturing and supply agreements to Gannet BioChem, an affiliate of Ampersand Management LLC d/b/a Ampersand Capital Partners (Ampersand) for consideration of $64.7 million in cash, net of transaction costs, and an approximate 20% equity interest at the time of close in Gannet BioChem.”
FILING10-K0001193125-26-104547cik 0000906709
“In 2012, we sold all of our rights to receive royalties from CIMZIA ® (for the treatment of Crohn's disease and other autoimmune indications) and MIRCERA ® (for the treatment of anemia associated with chronic kidney disease) under our collaborations with UCB Pharma (UCB) and F. Hoffmann-La Roche Ltd, respectively, to RPI Finance Trust (RPI), an affiliate of Royalty Pharma for $124.0 million.”
FILING10-K0001193125-26-104547cik 0000906709
“On March 4, 2024, we entered into a Securities Purchase Agreement with TCG Crossover Fund II, L.P. (TCG), pursuant to which we issued a pre-funded warrant (the TCG Pre-funded Warrant) to TCG to purchase 1,666,667 shares of Nektar's common stock for gross proceeds of $30.0 million (or a purchase price of $18.00 per share of common stock that can be issued upon exercise of the TCG Pre-funded Warrant).”
FILING10-K0001193125-26-104547cik 0000906709
“In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.”
FILING10-K0001193125-26-104547cik 0000906709
“In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.”
FILING10-K0001193125-26-104547cik 0000906709
“On February 12, 2024, for total cash consideration paid of $3.0 million, we repurchased the 552,307 shares previously sold to Bristol Myers Squibb Company (BMS).”
FILING10-K0001193125-26-104547cik 0000906709
“19 Nektar Therapeutics, Inc. San Francisco Bay Area 12,297 135,974 1.6% 0.8% 2030 4.1”
$20M relationship0.0× more of KRC’s book than NKTR’s
basisKRC fy2025 · closed 2025-12 $1.2BNKTR fy2025 · closed 2025-12 $55M
FILING
“Under the terms of the supply agreements, Gannet BioChem has agreed to manufacture and supply the PEG reagents for use in clinical trials of these drug candidates at prices defined within the agreements.”
FILING10-K0001193125-26-104547cik 0000906709
“On March 4, 2024, Nektar and HCR amended the 2020 Purchase and Sale Agreement to remove the cap on the royalties in exchange for $15.0 million.”
FILING10-K0001193125-26-104547cik 0000906709
“On February 24, 2025, we announced that we had entered into a collaboration agreement with TrialNet to evaluate rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus in a Phase 2 study. TrialNet will conduct the study with funding from the National Institutes of Health, primarily through the Special Statutory Funding Program for Type 1 Diabetes through the National Institute of Diabetes and Digestive and Kidney Diseases. Nektar will supply rezpegaldesleukin for the study and will retain all rights to the rezpegaldesleukin program under the collaboration.”
FILING10-K0001193125-26-104547cik 0000906709
“We previously entered into an equity distribution agreement (the April 2025 ATM Sales Agreement) with Piper Sandler & Co. and BTIG, LLC to sell shares of our common stock by any method permitted that is deemed to be an "at-the-market" equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act.”
FILING10-K0001193125-26-104547cik 0000906709
“We previously entered into an equity distribution agreement (the April 2025 ATM Sales Agreement) with Piper Sandler & Co. and BTIG, LLC to sell shares of our common stock by any method permitted that is deemed to be an "at-the-market" equity offering as defined in Rule 415(a)(4) promulgated under the Securities Act.”
FILING10-K0001193125-26-104547cik 0000906709
Watchlist prices, news filtered to it, and its next report on your desk.
Nektar Therapeutics
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 66.60 · gapped above the open, then crossed back over prior close. High/low 68.55 at 4:00 am ET, 65.83 at 2:45 pm ET.
Nektar Therapeutics has 5 disclosed suppliers and 12 disclosed customers. Each one is named in an SEC filing, either Nektar Therapeutics’s own annual report or the counterparty’s, and carries the sentence that discloses it.
NKTR (Nektar Therapeutics) has 5 disclosed suppliers and 12 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PIPR −2.06%, in financials.